MAZE
Maze Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$29.70
+7.88%Forward multiples
Based on analyst estimates
- P/E forward
- —
- P/E 2026E
- —
- P/E 2027E
- —
- P/E 2028E
- —
- P/S forward
- 157.37x
Trailing multiples
Trailing twelve months
- P/E TTM
- —
- PEG TTM
- —
- Price / book
- 3.64x
- Price / sales
- 82.49x
- Price / cash flow
- -15.49x
Enterprise value
- Enterprise value
- $1.3B
- EV / sales
- 64.96x
- EV / EBITDA
- -10.00x
- EV / EBIT
- -8.92x
- Market cap
- $1.6B
Trailing, forward and enterprise-value multiples for the requested listing · Data as of Jun 1, 2026